Pre-made Afasevikumab benchmark antibody ( Whole mAb, anti-IL17A therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-012
Anti-IL17A therapeutic antibody (Pre-made Afasevikumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL17A therapeutic antibody (Pre-made Afasevikumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||6ppg:HL:BA|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Autoimmune disorders;Inflammation|